Breaking News

PSSR aprimorada chega a Doom: The Dark Ages no PS5 Pro NFL Reporter’s Texts Reveal Fallout From Cheating Scandal With Married Coach FIFA World Cup In North America: When Football Serves Politics And Corporations – OpEd Watch Taylor Fritz vs Jan Choinski For a Healthier Long Island: New Office at SBU Links Climate, Community and Health Israel insists on troops in southern Lebanon as Rubio defends Iran deal in Middle East 2026 FIFA World Cup Livestream: How to Watch Today's Matches, Even for Free Guardians' Petey Halpin: Exiting starting nine

Signalz Online

Kerala Lottery

Osanni Bio raises $190 million Series B to advance therapeutics platform

Biotech Biotech Headlines

Osanni Bio raises $190 million Series B to advance therapeutics platform

Source: news.google.com

Published: Jun 24, 2026 12:56

Read Original Source

Osanni Bio raises $190 million Series B to advance therapeutics platform The Pharmaletter

Detailed source content is still being fetched from the original article. Use the source link above for the live story.

Courtesy Link

https://news.google.com/rss/articles/CBMitwFBVV95cUxNNW90a0JPVDNWVUVWeHhtbjlLaUNVSDBUV3pzTV92Q043ejBtZ2xUdU5mejVhMWhRZTIzY2w1RWRiY3NiR29QQ0pEam0yTFpSWXJkTFZ6d1BhQmxpQjV6bEhBSDNlSkJZTHZRbHpfYXMxOVd0OG9MY3kxa1JuNmtEUF9felVfR0dQTHFHb2JFSmw4a1BGSTltclFIa0pGenp6cUFkMGFvd1YxQzljWkhUaDFScFJ5UWM?oc=5

Related Stories

More from this topic and section

HHS, responding to China’s rise, moves to fast-track early drug research

MedTech Dive · 1 hour ago Biotech

HHS, responding to China’s rise, moves to fast-track early drug research

HHS, responding to China’s rise, moves to fast-track early drug research MedTech Dive

#Clinical Trials

At BIO, a glimpse behind Lilly and Chai’s partnership

statnews.com · 1 hour ago Biotech

At BIO, a glimpse behind Lilly and Chai’s partnership

At BIO, a glimpse behind Lilly and Chai’s partnership statnews.com

#Biotech Headlines

Ollin Bio lands $330 million Series B to fund late-stage retinal disease studies

The Pharmaletter · 1 hour ago Biotech

Ollin Bio lands $330 million Series B to fund late-stage retinal disease studies

Ollin Bio lands $330 million Series B to fund late-stage retinal disease studies The Pharmaletter

#Biotech Headlines

Corxel to advance oral obesity drug to Phase III trials

Clinical Trials Arena · 1 hour ago Biotech

Corxel to advance oral obesity drug to Phase III trials

Corxel to advance oral obesity drug to Phase III trials Clinical Trials Arena

#Clinical Trials

RQ Bio reels in $115M to take long-acting flu prevention antiviral into clinic

Fierce Biotech · 1 hour ago Biotech

RQ Bio reels in $115M to take long-acting flu prevention antiviral into clinic

RQ Bio reels in $115M to take long-acting flu prevention antiviral into clinic Fierce Biotech

#Biotech Headlines

From Trial-and-Error to Targeted Success: How Computational Disease Models Can Help Patients and Pharma Companies

MedCity News · 2 hours ago Biotech

From Trial-and-Error to Targeted Success: How Computational Disease Models Can Help Patients and Pharma Companies

From Trial-and-Error to Targeted Success: How Computational Disease Models Can Help Patients and Pharma Companies MedCity News

#Clinical Trials